Effect of perioperative dexmedetomidine on acute kidney injury after partial nephrectomy: a single-centre, randomised, double-blind, placebo-controlled trial
Abstract
Background: Acute kidney injury (AKI) is a frequent complication after partial nephrectomy. Dexmedetomidine appears to protect against kidney injury in both in vitro and in vivo. We tested the primary hypothesis that perioperative administration of dexmedetomidine would reduce the incidence of postoperative AKI after partial nephrectomy.
Methods: This randomised, double-blind, placebo-controlled trial was conducted in a tertiary care hospital in Beijing, China with 290 participants randomly assigned to receive dexmedetomidine or saline at a loading dose of 0.6 μg kg-1 followed by continuous infusion at 0.4 μg kg-1 h-1 intraoperatively. Dexmedetomidine (200 μg) was also used as an adjuvant for patient-controlled i.v. analgesia with sufentanil after surgery. The primary outcome was the incidence of AKI, defined according to the creatinine criteria of the KDIGO (Kidney Disease: Improving Global Outcomes) criteria for AKI.
Results: Two surgeries were cancelled after randomisation, leaving 288 participants (mean age [range]: 55 [20-79] yr; 32% female) for the modified intention-to-treat analysis. AKI occurred in 32/144 (22%) participants randomly assigned to dexmedetomidine, compared with 33/144 (23%) participants randomly assigned to saline (risk ratio 0.97; 95% confidence interval 0.63-1.49; P=0.888). Secondary outcomes, including postoperative serum cystatin C and serum creatinine levels and estimated glomerular filtration rate in postoperative 6 months, were not different…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 290 participants or records.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.